The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a pressure point for investors. Price erosion is a major worry amid increasing competition— including from knockoff versions of the drugs provided by telehealth pharmacies and coming patent expirations.

Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line with other European markets, the U.S. drugmaker said on Thursday. Lilly launched Mounjaro in the UK in February last year,

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.